Japanese cedar pollen allergy immunotherapy - Torii Pharmaceutical

Drug Profile

Japanese cedar pollen allergy immunotherapy - Torii Pharmaceutical

Alternative Names: Cedartolen; Cedartolen sublingual drop; TO-194; TO-194SL

Latest Information Update: 08 Nov 2014

Price : $50

At a glance

  • Originator Torii Pharmaceutical
  • Class Allergens; Antiallergics; Japanese cedar pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis

Most Recent Events

  • 08 Oct 2014 Launched for Allergic rhinitis in Japan (Sublingual)
  • 17 Jan 2014 Registered for Allergic rhinitis in Japan (Sublingual)
  • 25 Dec 2012 Preregistration for Allergic rhinitis in Japan (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top